You are so right my friend positive results in depression will raise the bar even higher, IMO AVNR know a considerable amount about the possibilities in this respect, the trial results will bring us some confirmation.
Excuse the pun but it really is mind boggling in respect of the permutations of treatments that may be available via one pill. This reminds me of the very first post
In the MS multi indication thread, from memory it ends with how cost effective a multi indication pill would be or some thing like that. The cost effective bit fits so well with our health system as well as many other EU countries.
We have talked about the pathways open to AVNR including the distribution systems (direct to hospitals) and many other aspects that could possibly come about.
Needless to say it is fantastic that we can see the possibilities gradually building up.
OBHF if you are tuned in my friend you often referred to KK being delighted mainly because of filling his pockets, well I’m also delighted and anticipating being over the moon.
Sarge I must dash off it is my lucky day. I’m off out to dinner with not one but two delightful lady’s.
Some Saturdays over the years have been less fun to sit down to. But really, looking at the numbers always helped keep things in perspective. Usually along the lines of, "well, it really isn't so bad after all." I'm telling you, market psychology is fascinating.
Some day I'll write a book. "What you're Thinking", by Sarge!
Thank you as always for your contribution to the discussion. And thank you for persevering with us as we try to grasp the profound difference in our health systems.
The real big fish on the horizon for me is depression. If that trial comes out positive, things will be jumping around here.
jhank, you are in the minority thinking that we'll be around a few years from now--most seem to think a BO is just around the bend. Who knows... I too like to think where we could be a few years--but the turbulent weather we will have to endure between now and then is more than a little disconcerting. (Some of picasso's best moments imo required little more than a flip of the wrist..) Best to all.
Never made a real product. Mixed generics together and called it a medical breakthrough. Even licensed Abreva (Rubbing Alcohol) to GSK because they couldn't risk being sued. Good luck--when analysts start issuing these obscene price targets, there's another goal in mind.
-Wall Street Toaster
P.S. Still not covering above $7. Many hedge funds are short as well. Look it up.
Sentiment: Strong Sell
It's really cool I put 25% of my wife's IRA in this and a nice chunk of our non retirement money in ANVR and it's becoming quite a ride thanks for the informative posts.
Hi Razor trust all is well. Just to let you know, I have not forgot about replying to you
as stated. The thing is this particular watch is complex and to achieve the accuracy it warrants a little time putting it together.
I have not invested in INSM yet Frank, but I'm watching it very closely. Looking at the chart, it might be in for some tax loss selling in the next 2-3 weeks. If it takes another plunge (hope for your sake it doesn't), it might be a good entry point.
I like the replies to your concern about the 26th. I think the concern is already baked in. And it didn't cause much of a ripple at that!
Hi Sarge – Thank you for this weeks round up much appreciated.
On the EU front, a Year or two back I thought AVNR were some what between a rock and a hard post.
In reality I’m sure they have stuck to there game plan all along. You will recall the partnering debates that took place back then, beyond doubt we are pleased that they have held out to date and did not short change us.
I was particularly interested in Burgoo note regarding his visit to the AVNR HQ thank you Burgoo “Everyone is asking about Europe and in my interpretation, it is being deliberately stalled until Avanir has more to offer for a partnership there “ Those few words were very telling IMO.
Just a diity from my ongoing research into Multi indication drugs.
The logic is simple: more indications result in a larger number of potential patients and, consequently, greater revenue opportunities. Obviously this logic only works if there is unmet clinical need and efficacy is demonstrated in each indication, so the number of drugs approved for multiple indications is relatively small. But where multiple indications are approved, annual sales can be counted in billions of dollars.
Biosimilar approval for multiple indications, looking forward to that bit.
Enjoy the rest of the weekend.
Thanks, Winkles, but I could imagine, without doubt, that your expression would have been markedly more profound and considerably more clever. Great to see you here.
Isn't trades just a gubber? LOLOL
Any other losing stock tips you'd like to suggest?
You were urging everyone to sell Avnr and pick up the "fun and exciting" Usat
Avnr this week= New 52 week high
USAT this week= New 52 week low
You have become quite the contrarian.....congrats.
You would have been more accurate if you stuck with your Avnr carney barking pom pom waving persona
Realized capital gains! Thank you Avanir!!!!
Sentiment: Strong Buy
Good morning All
Considering the process described in the first post of the thread (Please also refer to part 2 of the thread) IMO AVNR would have been hoping for plain sailing but more than likely pre-empting a little bit more work may be required due to the complexities of combination products.
Zacks Equity Research Article dated November 10, 2014 4:40 PM
Avanir Pharmaceuticals, Inc.’s shares were down 1.4% on news that the FDA has issued a disappointing preliminary feedback regarding the company’s new drug application for its Breath Powered intranasal delivery system, AVP-825. The company is looking to get AVP-825 approved for the treatment of migraine.
In its feedback, the FDA requested Avanir to conduct additional human factor testing on AVP-825 and optimize the product’s user interface. With the review under progress, the FDA may provide additional comments regarding the application. The review is expected to be completed by Nov 26, 2014.
Based on these developments, Avanir stated that the approval of AVP-825 will be delayed (previously expected by Nov 26, 2014).